REG - Oxford Biomedica PLC - Capital Markets Day and investor conferences

Oxford BioMedicaAnnouncement

03/03/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC0140Va&default-theme=true

RNS Number : 0140V  Oxford Biomedica PLC  03 March 2026

 

 

OXB announces date for Capital Markets Day and participation in upcoming
investor conferences

 

Oxford, UK - 3 March 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces the date of its
Capital Markets Day and participation at upcoming investor conferences.

Capital Markets Day

OXB will hold its Capital Markets Day at the London Stock Exchange Group
(LSEG) headquarters on 2 June 2026. Further details, including the agenda and
registration information, will be provided in due course.

Upcoming Investor Conferences

UBS European Healthcare Conference

Date: 3 - 4 March 2026

Location: London, UK

Berenberg UK Corporate Conference

Date: 17- 19 March 2026

Location: Watford, UK

25(th) Annual Needham Virtual Healthcare Conference

Date: 13 - 16 April 2026

Location: Virtual

Berenberg Midsummer Midcaps Conference

Date: 4 - 5 June 2026

Location: Ascot, UK

Investors attending any of the above conferences who would like to meet with
OXB are welcome to contact the Company's IR team via ir@oxb.com
(mailto:ir@oxb.com) .

Live webcasts and recordings of presentations, where available, will be
accessible under 'Results, Reports, Presentations & Webcasts' in the
Investor Relations section of OXB's website at www.oxb.com
(http://www.oxb.com) .

FY 2025 Preliminary Results

As previously announced, OXB will report its preliminary results for the
twelve months ended 31 December 2025 on 26 March 2026. OXB's management team,
led by Dr. Frank Mathias, Chief Executive Officer, Dr. Lucy Crabtree, Chief
Financial Officer, and Dr. Sébastien Ribault, Chief Business Officer, will
host a virtual analyst briefing at 13:00 GMT / 08:00 ET. To register, please
contact oxb@icrhealthcare.com (mailto:oxb@icrhealthcare.com) .

For details of other upcoming financial events, please refer to the Company's
investor calendar at https://oxb.com/investor-events/
(https://oxb.com/investor-events/) .

 

-Ends-

 

Enquiries:

 

OXB:

T: +44 (0) 1865 509 737 / E: ir@oxb.com (mailto:ir@oxb.com)

Sophia Bolhassan, Head of Investor Relations

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Sarah Elton-Farr / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFITVRIFIIR



            Copyright 2019 Regulatory News Service, all rights reserved